WZ8040 is primarily used in research settings as a potent and selective inhibitor of BET (bromodomain and extra-terminal) proteins, particularly targeting BRD4. It is employed in studies related to cancer biology, where it helps suppress the expression of oncogenes such as MYC. Due to its ability to modulate gene transcription, WZ8040 is investigated for its antitumor activity in hematological malignancies and solid tumors. It has shown promise in preclinical models for leukemia, lymphoma, and certain types of lung cancer by inducing cell cycle arrest and apoptosis. Additionally, WZ8040 is utilized to explore epigenetic regulation mechanisms, making it a valuable tool compound in drug discovery and molecular pharmacology.